Data compiled by Redley Lamar · ChainSifter Intelligence
1Suppliers
6Customers
1Debt Items
18Related Chains
Source-Backed Evidence Depth
Connect Biopharma Holdings Limited (CNTB) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
9Total relationships
1Distinct source URLs
3High confidence
0.738Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Reciprocal relationship from VTYX graph: Reciprocal relationship from CNTB graph: Reciprocal relationship from VTYX graph: Reciprocal relationship from CNTB graph: Reciprocal relationship from VTYX g…
Connect Biopharma Holdings Limited Customers
Ticker
Name
Confidence
Evidence
SIMCERE
SIMCERE
92%
The Company recognized the revenue associated with the transfer of the intellectual property and know-how and transfer of the current manufacturing process were recognized at a point in time upon suc…
Reciprocal relationship from VTYX graph: and evaluation of individual patient response. Moderate-to-severe psoriasis requires phototherapy or systemic therapies, such as retinoids, methotrexate, cycl…
PANACEA-INNOVATION-LIMITED
PANACEA-INNOVATION-LIMITED
62%
ated stand-alone selling price for the license using a discounted cash flows model, which is an income approach. In estimating the stand-alone selling price for each performance obligation, the Compa…
Reciprocal relationship from SIM graph: Reciprocal relationship from CNTB graph: Reciprocal relationship from SIM graph: Reciprocal relationship from CNTB graph: Reciprocal relationship from SIM grap…
SIMCERE-PHARMACEUTICAL-CO-LTD
SIMCERE-PHARMACEUTICAL-CO-LTD
62%
idered to be ordinary share equivalents and are included in the calculation of diluted net loss per share only when their effect is dilutive. Because we incurred a net loss for the three months ended…
SIMCERE-PHARMACEUTICAL-GROUP-LTD
SIMCERE-PHARMACEUTICAL-GROUP-LTD
62%
idered to be ordinary share equivalents and are included in the calculation of diluted net loss per share only when their effect is dilutive. Because we incurred a net loss for the three months ended…
